Ovarian Cancer Coverage from Every Angle
Editor:
Joyce F. Liu, MD, MPH
Advertisement
Advertisement

Videos

Alexander Olawaiye, MD, on The ROSELLA Trial in Platinum-Resistant Ovarian Cancer

Sven Mahner, MD, on Advanced Ovarian Cancer: Radical Upfront Surgery

Rachel N. Grisham, MD, on Avutometinib Plus Defactinib in Low-Grade Serous Ovarian Cancer

Gottfried E. Konecny, MD, on Targeting Folate Receptor Alpha in Ovarian Cancer

Lainie P. Martin, MD, Antibody-Drug Conjugates and Ovarian Cancer

Daniela E. Matei, MD on Biology-Driven Therapy for Ovarian Cancer

Elizabeth H. Stover, MD, PhD, on Nivolumab and Bevacizumab: Genomic Biomarker Analysis of an Ovarian Cancer Regimen

Kala Visvanathan, MD, on Clinical Implications of Using Cholesterol-Lowering Drugs to Treat Ovarian Cancer

Lucy Gilbert, MD, on Mirvetuximab Soravtansine Plus Bevacizumab for Platinum-Agnostic Ovarian Cancer

Tingyan Shi, MD, PhD, on Clinical Implications of Using Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer

Joyce F. Liu, MD, on Clinical Implications of Using Cediranib Plus Olaparib for Ovarian Cancer

Theresa L. Werner, MD: Talking With Patients About Ovarian Cancer Clinical Trials

Theresa L. Werner, MD, on Ovarian Cancer and the Immunotherapy Revolution

Megan Grudem, APRN, CNP, on PARP Inhibitors in Ovarian Cancer: Managing Side Effects

Isabelle Ray-Coquard, MD, PhD, on the Safety of Combination Regimens With Bevacizumab

Ursula A. Matulonis, MD, on Genetic Profiling and PARP Inhibitors

Ursula A. Matulonis, MD, on Educating Patients About the Hematologic Risks of PARP Inhibitors

Ursula A. Matulonis, MD, on Current Therapies vs Novel Antibody-Drug Conjugates

Mansoor Raza Mirza, MD, on Reducing Toxicity Associated With PARP Inhibitors in Ovarian Cancer

Mansoor Raza Mirza, MD, on the Potential Role of PARP Inhibition Plus Immunotherapy in Ovarian Cancer

Yoland C. Antill, MD, on the Potential Role for Durvalumab in Treating Advanced Endometrial Cancer

Yoland C. Antill, MD, on Using a PARP Inhibitor in Maintenance Therapy for Ovarian Cancer

Eric Roeland, MD, on Prophylactic Strategies for Highly Emetogenic Chemotherapy

Domenica Lorusso, MD, PhD, on Ovarian Cancer: The Algorithm of Treatment

Robert L. Coleman, MD, on Secondary Surgical Cytoreduction Followed by Chemotherapy for Ovarian Cancer

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Neeraj K. Arora, PhD, on Patient-Centered Care in Clinical Practice

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Domenica Lorusso, MD, PhD, on Recurrent Ovarian Cancer: Treatment Update

Ursula A. Matulonis, MD, and Stéphanie Gaillard, MD, PhD, on Ovarian Cancer: Upfront Therapy

Jeremy Warner, MD, on Patient Navigation: The Proactive Approach

Charles von Gunten, MD, PhD, on Opioids for Managing Cancer Pain

Ursula A. Matulonis, MD, and Jacob Korach, MD, on AML Risk in Ovarian Cancer: Results From the SOLO2 Trial

Ursula A. Matulonis, MD, and Panagiotis A. Konstantinopoulos, MD, PhD: Ovarian Cancer Update: Expert Perspective

Catherine B. Earley, MS, ANP-BC, ACNP-BC, on Managing Olaparib-Induced Nausea

Ursula A. Matulonis, MD, on the Value of the Ovarian Cancer Guidelines

Lisa Arvine, MSN, WHNP-BC, ANP-BC, on Managing Olaparib-Induced Fatigue

Susana M. Campos, MD, MPH, on the Role of PARP Inhibitors in the Treatment Landscape of Ovarian Cancer

A Patient's Story: How NCCN Guidelines for Patients® Helped Me and My Caregiver

A Patient's Story: NCCN Guidelines for Patients® Helped Me Ask The Right Questions

The JNCCN Spotlight

Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved